Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.43 |
| ▸ | OGFRL1 | Q5TC84 | 9/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8718634 | 0.98 | KDM4E (0.49) | KDM4EOPRM1OPRK1OGFRL1OPRD1 | |
| SCHEMBL2078485 | 0.97 | HTR3A (0.46) | KDM4EOPRM1OPRK1OGFRL1OPRD1 | |
| SCHEMBL31429395 | 0.94 | CYP3A4 (0.44) | KDM4EOPRM1OPRK1OGFRL1OPRD1 | |
| SCHEMBL5316749 | 0.87 | SSTR4 (0.49) | — | |
| SCHEMBL8876610 | 0.87 | ELANE (0.51) | KDM4EOPRM1OPRK1OGFRL1OPRD1 | |
| SCHEMBL8713323 | 0.87 | HTR3A (0.45) | KDM4EHTR3AHTR3ESLC22A2HTR3B | |
| SCHEMBL8718851 | 0.85 | HTR3A (0.44) | KDM4EOPRM1OPRK1OGFRL1OPRD1 | |
| SCHEMBL8717365 | 0.84 | HTR3A (0.48) | KDM4EOPRM1OPRK1OGFRL1OPRD1 | |
| SCHEMBL21725181 | 0.83 | ELANE (0.54) | KDM4EHTR3AHTR3ESLC22A2HTR3B | |
| SCHEMBL25233771 | 0.82 | MEN1 (0.40) | KDM4EOPRM1OPRK1OGFRL1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351704-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | claimed |
| CN-1922175-A | As 5-HT4Indazole-carboxamide compounds as receptor agonists | THERAVANCE INC (US) | 2007-02-28 | — | — | CN | claimed |
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-09-08 | — | — | US | claimed |
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | AMGEN INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | AMGEN INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220363694-A1 | N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF | AMGEN INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-3837262-A1 | N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF | Amgen Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020036940-A1 | N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF | AMGEN INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20100261716-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7674908-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080146807-A1 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-19 | — | — | US | disclosed |
| WO-2008054748-A2 | INDAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| US-7351704-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| CN-1922175-A | As 5-HT4Indazole-carboxamide compounds as receptor agonists | THERAVANCE INC (US) | 2007-02-28 | — | — | CN | disclosed |
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-09-08 | — | — | US | disclosed |
| EP-0708105-B1 | 5-HT4 receptor agonists | NISSHIN FLOUR MILLING CO (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5684003-A | GASTROINTESTINAL DISORDERS OR ANTIULCER AGENTS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-11-04 | — | — | US | disclosed |
| EP-0708105-A1 | 5-HT4 receptor agonists | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | HTR4, HTR5A, HTR3C | KDM4E 1798/4885OPRM1 194/4885OPRK1 113/4885 |
| US-20080146807-A1 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR3B | KDM4E 1226/4885OPRM1 145/4885OPRK1 127/4885 |
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | CYP3A7, CYP51A1, NT5C3B | KDM4E 586/4885OPRM1 4322/4885OPRK1 3832/4885 |
| US-20220363694-A1 | N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF | CYP3A7, CYP51A1, NT5C3B | KDM4E 586/4885OPRM1 4322/4885OPRK1 3832/4885 |
| US-20100261716-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR3B | KDM4E 1226/4885OPRM1 145/4885OPRK1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.